Beacon TPD – H1 Landscape Review Full Report
About the report
- Through H1 2022, there have been 88 newly disclosed TPD drugs, including Amgen and Arrakis’ RNA degraders, Ambagon Therapeutics’ molecular glue pipeline and Degron Therapeutics’ TPD pipeline.
- There were 67 TPD drug updates, of which 46% were preclinical data updates for records including KT-333, MRT-2359 and NX-5948.
- 14 companies joined the TPD space, including TRIANA Biomedicines which launched in April 2022 with $110M total funding to develop their molecular glue platform, and the AI startup Protai Bio which came out of stealth mode in January 2022 following an $8M seed financing round.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements